Hevylite®
Heavy Chain/Light Chain Analysis
Hevylite Immunoglobulin Heavy Chain/Light Chain Analysis
Intact immunoglobulin molecules contain unique junctional epitopes between the heavy chain and light chain constant regions. These are the target of the Hevylite antibodies. They can identify, separately, the different light chain types of each immunoglobulin class i.e. IgGk, IgGl, IgAk, IgAl, IgMk, IgMl. The molecules are then measured in pairs e.g. IgGk/IgGl to produce ratios of involved monoclonal immunoglobulin / background uninvolved polyclonal
concentrations, in the same manner as serum free light chain k and l ratios when using Freelite.
References
1. Katzmann JA, et al. Serum Reference Intervals and Diagnostic Ranges for Free k and Free l Immunoglobulin Light Chains: Relative Sensitivity for Detection of Monoclonal Light Chains. Clin Chem 2002; 48:1437-1444
2. Dispenzieri A, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009; 23:215–224
3. Katzmann JA, et al. Screening Panels for Detection of Monoclonal Gammopathies. Clin Chem 2009; 55:1517-1522
immunoglobulin
4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN GuidelinesTM
Comprehensive Cancer Network, Inc. All rights reserved.
5. Hill PG, et al. Serum Free Light Chains: An Alternative to the Urine Bence Jones Proteins Screening Test for Monoclonal Gammopathies. Clin Chem 2006; 52:1743-1748
6. Katzmann JA, et al. Elimination of the Need for Urine Studies in the Screening Algorithm for Monoclonal Gammopathies by Using Serum Immunofixation and Free Light Chain Assays. Mayo Clin Proc 2006; 81:1575-1578
7. Smith A, et al. Guidelines on the diagnosis and management of multiple myeloma. Br J Haematol 2005; 132:410-451
8. Abadie JM, et al. Assessment of Serum Free Light Chain Assays for Plasma Cell Disorder Screening in a Veterans Affairs Population. Ann Clin & Lab Sci 2006; 36:157-162
9. Bakshi NA, et al. Serum Free Light Chain (FLC) Measurement Can Aid Capillary Zone Electrophoresis in Detecting Subtle FLC-Producing M Proteins. Am J Clin Pathol 2005; 124: 214-218
Target epitopes (in black) for Hevylite antibodies are on the constant regions between the heavy and light chains of immunoglobulin molecules.
Hevylite assays are currently available as “research use only” in the USA.
Visit
www.thebindingsite.com for the latest information. More
10.Nowrousian MR, et al. Serum Free Light Chain Analysis and Urine Immunofixation Electrophoresis in Patients with Multiple Myeloma. Clin Cancer Res 2005; 11: 8706-8714
11. Bradwell AR, et al. Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003; 361:489-491
12. Lachmann HJ, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003; 122:78-84
13.Drayson M, et al. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001; 97: 2900-2902
14. Abraham RS, et al. Correlation of Serum Immunoglobulin Free Light Chain Quantification with Urinary Bence Jones Protein in Light Chain Myeloma. Clin Chem 2002; 48:655657
15.Mead GP, et al. Serum free light chains for monitoring multiple myeloma. Br J Haematol 2004; 126:348-354
16.Hajek R, et al. Free Light Chain Assays for Early Detection of Resistance to Bortezomib-Based Regimens. Haematologica 2007;92 (s1):Abstract 0257 93
17.Mösbauer et al. Monitoring serum free light chains in patients with multiple myeloma who achieved negative immunofixation after allogeneic stem cell transplantation. Haematologica 2007; 92:275-276
18.Dawson et al. Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains. Haematologica 2007; 92:143-144
19. Kühnemund A, et al. ‘Light chain escape-multiple myeloma’ - an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring. J Cancer Res Clin Oncol 2009; 135:477-484
) for Multiple Myeloma V.1.2011.©2010 National
12
More Information on Hevylite
Contact your local office
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24